Clinical trial
Belatacept Evaluation of Nephroprotection and Efficacy as First-line…
NCT00256750 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00256750 |
|---|---|
| Title | Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) |
| Official title | Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) |
| Acronym | BENEFIT |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Transplantation, Chronic Kidney Failure |
| Intervention type | Drug |
| Interventions | Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive) |
| Enrollment | 738 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Apr 1, 2015 |
| First posted | Nov 22, 2005 |
| Last update posted | Aug 19, 2016 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, India, Israel and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: